Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VipAlbumin in Elderly Sarcopenia
NCT05869383Phase 3Completed
- Sponsor
- Universitas Sriwijaya
- Start
- May 2023
- Primary completion
- Sep 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Sarcopenia comparing Placebo with VipAlbumin (2 arms). Primary endpoints: Insulin-like Growth Factor 1 at 2 weeks and Interleukin 6 at 2 weeks. Started May 2023; status: completed.
02
Drugs
VipaAlim
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on NCT05869383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05869383.